Quick Answer
VYNE Therapeutics Inc. reported Operating Income Loss of -$29.75 million for the year ending 2025.
- VYNE Therapeutics Inc. showed an increase of +31.8% in Operating Income Loss from 2024 to 2025.
- This data is from VYNE Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), VYNE Therapeutics Inc.'s Operating Income Loss has declined by 545.6%.
- Historical annual values: Fiscal year 2025: -$29.75 million | Fiscal year 2024: -$43.64 million | Fiscal year 2023: -$29.26 million | Fiscal year 2022: -$34.30 million | Fiscal year 2021: -$38.91 million | Fiscal year 2020: -$252.55 million | Fiscal year 2019: -$95.87 million | Fiscal year 2018: -$74.89 million | Fiscal year 2017: -$29.59 million | Fiscal year 2016: -$14.33 million | Fiscal year 2015: -$4.61 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: